TScan Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

TScan Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $152.41 million for the year ending 2025.

  • TScan Therapeutics, Inc. showed a decrease of -14.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 338.1%.
  • Historical annual values: Fiscal year 2025: $152.41 million | Fiscal year 2024: $178.69 million | Fiscal year 2023: $133.36 million | Fiscal year 2022: $120.03 million | Fiscal year 2021: $161.41 million | Fiscal year 2020: $34.79 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: